Patents

Cell>Point is pursuing an aggressive domestic and international patent protection program for each of the licensed technologies. The Company's product development and clinical trial scheduling is geared toward preserving as much of the remaining patent life for each commercialized product as possible. With the exception of the cardiology patent application involving EC Technology, the owner of the EC Technology patents (domestic and international) is the Board of Regents of The University of Texas M.D. Anderson Cancer Center. Cell>Point has full patent rights for life of patent.

The following is the patent issuance and application status of each of the technology platforms.

1. Initial EC Technology U.S. patent issued (US 6,692,724 B1)
2. Second EC Technology U.S. patent issued (US 7,067,111)
3. Third EC Technology U.S. patent issued (US 7,223,380)
4. Fourth EC Technology U.S. patent issued (US 7,229,604)
5. Fifth EC Technology U.S. patent issued (US 7,615,208)
6. Sixth EC Technology U.S. patent issued (US 7,582,281)
7. Seventh EC Technology patent issued (US 7,632,484)
8. First Australia EC Technology patent issued (2001275210)
9. Second Australia EC Technology patent issued (200329761)
10. China EC Technology patent issued (ZL 01811605.1)
11. Hong Kong EC Technology patent issued (HK 1056682)
12. India EC Technology patent issued (226068)
13. Israel EC Technology patent issued (153281)
14. South Korea EC Technology patent issued (784120)
15. All remaining domestic and international EC Technology patent applications are in various stages of review.
16. In-Situ Hydrogel U.S. patent application approved and awaiting issuance (App. No. 10/024/678).
17. All international In-Situ Hydrogel patent applications are pending and in various stages of review.
18. Beta Cell Technology U.S. patent issued (US 7,611,693).
19. Beta Cell Technology international applications are under review.
20. Dual Agent Technology U.S. patent application under review (APN 11/326,117)
21. Dual Agent Technology international applications are under review
22. N4 Technology U.S. patent application under review (APN 11/737,694)
23. N4 Technology international applications are under review